secwatch.observer — SEC 8-K summary
======================================

Issuer:     Petros Pharmaceuticals, Inc. (PTPI)
CIK:        0001815903
Form:       8-K
Filed at:   2023-07-13T23:59:59+00:00
Accession:  0001104659-23-080765
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 3.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Petros Pharmaceuticals raises $15M via private placement to advance OTC STENDRA
-------------------------------------------------------------------------------

- Issued 15,000 Series A Convertible Preferred shares (stated value $1,000 each) and warrants for up to 6,666,668 common shares at $2.25.
- Gross proceeds of $15M; cash on hand $8.3M (March 31, 2023); expect funding through end of 2024.
- Proceeds to support OTC switch program for STENDRA (erectile dysfunction) including FDA engagements and pivotal Label Comprehension Study.
- Placement led by largest existing shareholders; directors/officers holding ~29% of common stock agree to vote for Nasdaq approval.
- Closing expected July 17, 2023; Katalyst Securities served as placement agent (8% cash fee + warrants).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815903/000110465923080765/0001104659-23-080765-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815903/000110465923080765/tm2321191d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-080765

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer